23-ka Maarso 2023: Daawaynta unugyada kansarka ee hore iyo kuwa hore ee ay samaysay Shanghai biotech Oricell waxay heshay $45 milyan oo dheeri ah oo maalgelin ah, shirkaddu waxay ku dhawaaqday Talaadadii.
Ka dib bandhiga ASCO sannadkii hore oo leh GPRC5D-ku hagaya daawaynta CAR-T ee myeloma badan, Oricell wuxuu kor u qaaday $120 milyan Taxane B bishii Luulyo. Maalgashadayaasha cusub ee Qiming Venture Partners iyo C&D Equity Industry Equity Investment oo ay ku xigto maalgashadayaasha jira ee RTW Investments iyo Hay'adda Maalgashiga Qatar ayaa horseeday kor u kaca ugu dambeeyay, kaas oo ah ballaarinta wareegaas.
Shirkadda bayotechnoolajiyadda ayaa sheegtay in lacagaha cusub ee la helay loo isticmaali doono ugu horrayn cilmi baarista caafimaadka ee Maraykanka.
Oricell waxa uu ka shaqaynayaa tiro ka mid ah Daaweynta CAR-T iyo musharixiinta lidka ku ah buro adag. Koox bukaan ah oo daawaynta u adkaysata Meelo badan uga jawaabay Oricell's GPRC5D-ku hagayo CAR-T oo leh 100% heerka jawaab celinta guud iyo 60% jawaabcelin adag oo dhamaystiran ee tijaabada Wajiga I ee lagu soo bandhigay ASCO.
Waxaa laga yaabaa inaad jeceshahay inaad akhriso: CAR T-Cell daaweynta Shiinaha
Gaar ahaan, Oricell wuxuu iftiimiyay koox shan bukaan ah oo hore u helay BCMA Daaweynta CAR-T. Sida laga soo xigtay shirkadu, hal jawaab oo qayb ah, laba "jawaab qaybeed aad u wanaagsan," iyo laba jawaabo oo dhamaystiran oo adag ayaa dhammaantood la helay. Iyo dabagal dhexdhexaadin ah oo u dhexeeya 35 ilaa 281 maalmood, dhamaantood waxay ahaayeen kuwo bilaa horumar ah taariikhda goynta ASCO.
Sida laga soo xigtay Oricell, oo hadda ku jirta marxaladda IND-awood u leh, waxay rajaynaysaa inay kordhiso tijaabinta daawaynta CAR-T ee ay GPRC5D ku hagto Maraykanka.
Intaa waxaa dheer, Oricell waxay leedahay daawaynta unug ee CAR-T ee GPC3-dugsato oo la yiraahdo Ori-C101, kaas oo ay ku barato kansarka hepatocellular sare.
Daaweynta T-Cell-ka Baabuurka Waxay ka mid tahay daawaynta horumarsan ee noocyada kansarka dhiigga qaarkood. Waxa socda in ka badan 750 tijaabada caafimaadka ee CAR T-Cell therapy ee Shiinaha hadda. Bukaanada raba inay isdiiwaangeliyaan waxay la xiriiri karaan Faa'iidada Kansarka Khadka caawinta bukaanka ee WhatsApp + 91 96 1588 1588 ama emayl ku soo dir info@cancerfax.com.
